SciClone Pharmaceuticals, Inc. to Report First Quarter 2009 Results on May 11

FOSTER CITY, CA--(Marketwire - April 29, 2009) - SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it plans to report first quarter 2009 results on Monday, May 11, 2009. SciClone will host a conference call to give a business and product update at 4:30 pm ET that day. The call will be hosted by Friedhelm Blobel, Ph.D., President and CEO, and Gary Titus, Senior Vice President and CFO.

LIVE CALL:      877-627-6544 (U.S./Canada)
                719-325-4858 (International)
REPLAY:         888-203-1112 (U.S./Canada)
                719-457-0820 (International)
                Passcode:  7704836
                (Replay available from Monday, May 11, 2009 at 8:00 p.m.
                ET until 11:59 p.m. ET on Monday, June 8, 2009)

The conference call will contain forward-looking statements. Interested parties who wish to listen to the webcast should visit the Investor Relations section of SciClone's website at www.sciclone.com. The information provided on the teleconference is only accurate at the time of the conference call, and SciClone will take no responsibility for providing updated information except as required by law.

About SciClone

SciClone Pharmaceuticals (NASDAQ: SCLN) is a for-profit, global biopharmaceutical company with a substantial international business and a product portfolio of novel therapies for cancer and infectious diseases. SciClone is focused on achieving international sales growth, a cost-containing clinical development strategy and focused expense management. ZADAXIN is sold in over 30 countries for the treatment of hepatitis B and hepatitis C, certain cancers and as a vaccine adjuvant. SciClone's pipeline of phase 2 and 3 drug candidates includes thymalfasin for stage IV melanoma, for which SciClone has reached agreement with the FDA on the design of a phase 3 trial; RP101 in phase 2 in a phase 2 trial for the treatment of pancreatic cancer; SCV-07 in a phase 2 trials for the delay of onset of severe oral mucositis in patients receiving chemoradiation therapy for the treatment of cancers of the head and neck; and, awaiting approval in China, DC Bead™ for the treatment of liver cancer. For additional information, please visit www.sciclone.com.